A new Form 4 filing with the U.S. Securities and Exchange Commission (SEC) published this week confirms that Spear Catherine Eva, Director, Chief Executive Officer and 10% owner of healthcare apparel brand FIGS, Inc. (NYSE: FIGS), sold approximately $79,672,395 worth of company stock on November 9, 2026. The transaction was executed at an average price of $38.22 per share, per filing details, with no additional open market sales from Eva listed in the 90 days prior to the transaction.

Founded in 2013, FIGS carved out a niche as a direct-to-consumer disruptor of the staid, low-quality medical apparel market, offering premium, performance-focused scrubs, loungewear, accessories and footwear tailored to healthcare workers. The brand has expanded rapidly over the past decade, moving beyond e-commerce to operate 32 brick-and-mortar locations near major U.S. hospital networks, and launching dedicated marketplaces in the U.K. and Australia in 2025. As of the third quarter of 2026, FIGS holds an estimated 18% share of the $12 billion U.S. medical apparel market, making it the second-largest player in the space, with 4.2 million active customers and a 78% repeat purchase rate for its core scrub line. Year-to-date as of November 8, 2026, FIGS stock has risen 42%, outperforming the S&P 500 consumer discretionary sector’s 11% gain over the same period.

Market analysts note that there are a range of plausible, non-operational reasons for the high-value share sale, which represents roughly 8% of Eva’s total outstanding holdings in the company. The most common explanation for large insider sales among C-suite executives is personal financial diversification: as a 10% owner and long-time leader of FIGS, the majority of Eva’s net worth is likely tied to company stock, making a partial sale a rational move to spread personal financial risk. Other potential drivers include tax planning ahead of proposed 2027 federal capital gains tax hikes, or estate planning arrangements for high-net-worth individuals. The filing did not specify whether the sale was executed under a pre-planned Rule 10b5-1 trading plan, which would allow executives to schedule stock sales in advance to avoid allegations of trading on non-public information. There is no public indication to date that the sale is tied to unreported negative operational performance at FIGS: the company beat third-quarter 2026 revenue and adjusted EPS estimates by 7% and 12% respectively in its October 27 earnings release, and reaffirmed its full-year 2026 guidance for 19% year-over-year revenue growth.

For retail and institutional investors, the transaction does not on its own signal a bearish outlook for the company, analysts emphasize. Eva still retains a more than 9% stake in FIGS after the sale, meaning she has significant financial incentive to drive long-term share price growth. Historically, single large insider sales from 10% owners are far less predictive of future stock performance than coordinated sales across multiple C-suite and board members, or repeated sales from the same executive over a short time frame. Investors who are concerned about the transaction are advised to monitor upcoming SEC filings for additional context, and to cross-reference insider trading activity with broader operational metrics including customer retention rates, international expansion progress, and demand for the brand’s expanding line of non-scrub lifestyle apparel for healthcare workers.

As of press time, FIGS has not issued an official statement addressing Eva’s share sale. The company is scheduled to host its fourth-quarter and full-year 2026 earnings call on December 14, where leadership may provide additional context on recent insider trading activity and future growth plans.

Market commentary for information only — not financial advice.